In an ongoing effort to reduce the risks of potential exposure to COVID-19, UF Health continues to update guidance on PPE (Personal Protection Equipment) use in patient-care areas. These updates impact the current PPE requirements for UF research staff. Changes and clarifications include the following: At a minimum,…
The University of Florida has now begun Stage 3 in the process for reengaging on-campus research activities which have been interrupted by the COVID-19 pandemic.
UF|Research and OCR have each recently provided UF-specific research resumption guidance. The information in this webinar should not to be used to conflict with UF Guidance, but there may be useful information shared that we can all glean something from. Additionally, there are possible CE’s for certain accrediting organizations if there is an interest there.
The University of Florida has now begun Stage 2 in the process for reengaging on-campus research activities which have been interrupted by the COVID-19 pandemic.
The UF Office of Clinical Research has published guidance for resuming clinical research projects, which applies to all UF health-related human subjects research.
The University of Florida is beginning the process for reengaging on-campus research activities which have been interrupted by the COVID-19 pandemic.
UF Health Investigational Drug Services has developed a position statement on the issue of shipping dispensed Rx to research participants.
The UF Institutional Biosafety Committee has issued guidance regarding important biosafety rules and regulations pertaining to COVID-19.
Most of the UF workforce has transitioned to telework during the COVID-19 pandemic. UF|Research has created a webpage that offers suggestions for activities that advance research productivity while also keeping an active work status.
Investigators may need to alter protocols to minimize the spread of COVID-19. The following outlines if/when IRB needs to be notified.